Member Info for Soupdragon78

imho, not naive, just has his hands tied by the situation.

The company are limited in how much they can raise by the stock market rules, combined with the current climate for raising money.

The key elements here are that the money was raised for additional work and its placed with an institution, not just retail.

Insti holds all the cards if you need cash. Hence the price.

Mulder, you’ll get an opportunity to ask your questions to the company directly soon.

Poster who claimed to have done billions in deals over decades came onto a board, setting up multiple identities and claiming NXP004 couldn’t possibly be linked to Lynparza and was wrong.

Gros bisous.

Potential IPF add-on NXP002 reduces fibrosis markers: Early tests

Nuformix plans testing in lung tissue samples from patients, healthy volunteers

https://pulmonaryfibrosisnews.com/news/early-lab-tests-ipf-add-on-nxp002-reduces-fibrosis-markers/

So tetchy about everything Mulder.

For someone who has done billions in deals over decades in Pharma, your need to pointlessly post on an anonymous bulletin board at 11pm on a Friday night about a tiny mcap having received an ISR is quite telling.

The NXP004 patent has now gone through the PCT chapter 1 process and confirmed as both novel and inventive. So it moves to the individual countries patent offices.

As usual people sell on news, especially when the company is saying next news in over a period of weeks and months.

Most of the twitter / social media crowd will have sold.

Feels like they've gone back to bed

FX m, the current standard of care drugs don’t halt progression of fibrosis, they only slow it.

Coincidentally, yesterday Avalyn gave an update on their inhaled version of pirfenidone, this again only delayed the progression of the fibrosis, rather than halting or reversing.

Could do with hearing about NXP004 and what's happening (or not) there.

3 key takeouts
- No toxic events and shows good tolerability
- tested as a stand alone as well as adjunctive. Showed strong anti-fibrotic effects as a stand alone.
- In combination after 4 days the tests showed lower fibrosis biomarkers than at the commencement.

Dan's interview now available

https://www.***************************/nuformix-nxp002-meets-best-case-scenario-objectives-video/4121112454

At least the tea leaf chart things predicted this.

Sounding like Oxilio have been fundraising.

Lets just say it depends who you are promoting it to.

Big investors and companies interested won't be looking at the twitter feed. Thats only for small time traders.

Nice to see, although like the website its a bit pointless.

Interesting Robbo.

Would it be a good thing for a CEO to go onto a public forum and talk about the biggest shareholder of a company?

Thanks wheaten, what has been said that make it sound plausible?

Jiving, is it possible for someone to sign up to telegram using any name they choose?